N
Google TrendLAMINE YAMAL (2000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Enfortumab Vedotin Plus P" (30 stories)

Top Headline Story

Enfortumab Vedotin Plus Pembro Sustains Long-Term Efficacy in Advanced Urothelial Carcinoma
Lead StoryTargeted Oncologytech
May 29

Enfortumab Vedotin Plus Pembro Sustains Long-Term Efficacy in Advanced Urothelial Carcinoma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQNmNLb3haY3RIWjVkeW1qNHBZVFpzUzJnbXNxRl95ZjdnSjl3M1U1LWFXTktEMHMtTW1zdVJlUDJQZURrSDZlVXNKMElRb2ktVXI2c29BLWtGWFNheldhN2ZMMlh2VldHaHhsWGZJUENRTEt2c08wbFR4QURqRzBzRWFOSy1UdzZ2RXM3WnQ3Q3RLdFhRZS1fVzFRa3U4SWVyWm9IT2IxSEQ5bmdPY1FDVHZrelp2Z3dLZGxSLTB1TVpiZw?oc=5" target="_blank">Enfortumab Vedotin Plus Pembro Sustains Long-Term Efficacy in Advanced Urothelial Carcinoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+21m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+31m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories
500+31m ago

pope francis

The Myth of St. Francis

Filter stories
500+31m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "Enfortumab Vedotin Plus P"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Updated EV-302 Trial Results Show Improved Survival With EV+P in Metastatic Urothelial Cancer
Oncology News Centralgeneral

Updated EV-302 Trial Results Show Improved Survival With EV+P in Metastatic Urothelial Cancer

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQcVlxLWhqZk8tem1Rd0tfVldRaXRSUlJhMmQ0NUpLS0FmLW00Y1M0WGZpTGlBQlhoaXlqM2hLN21OVTlQV2NGQ2hFdkVBWDYxQ3A0SElnaE9rbUc2S1B4R2VXSFQyLW4tMjBKVkU0RmgtQWF6dDlyRVFpaU1KWXlWU2JWZlY3ZzllR0JuZzdFVzBmNDBvUlBIUUxuM0RfeGpTWDBzN21NQy1ObVhaTlNsTk5UOUlQcVl1TUdndDN6NW1BZGN0QXBV?oc=5" target="_blank">Updated EV-302 Trial Results Show Improved Survival With EV+P in Metastatic Urothelial Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Updated EV-302 Data Reinforce Enfortumab Vedotin Combo’s Durability in Urothelial Carcinoma at ASCO 2026
OncLivegeneral

Updated EV-302 Data Reinforce Enfortumab Vedotin Combo’s Durability in Urothelial Carcinoma at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOcTFERjFjWUxPMnRmV1JEZUtjQk9fOTdXa1Bqa3ppeUsxbjRsZzRRUVU5bzh5NWk0QUZBWm1CRkhrLUN6NlVIT0ZCTHh4Z25kY1M1VkFudWFCWng5dGJtalpUTUtUeUI1ckpzUXdpbnpLYWlGOUFEMW03d1hsSkNmRnYxcWpCdE4xZmljMXctWDVualBZWG01a0EwTEhSQjBqZ19HQkZ4Rml2M3lfamJvODhpbmIzcUtMNlR6QVQ1bjVtSGJ3Y1NGSVJYWlg0QQ?oc=5" target="_blank">Updated EV-302 Data Reinforce Enfortumab Vedotin Combo’s Durability in Urothelial Carcinoma at ASCO 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Enfortumab Vedotin/Pembrolizumab Maintains OS Benefit in Urothelial Carcinoma
CancerNetworktech

Enfortumab Vedotin/Pembrolizumab Maintains OS Benefit in Urothelial Carcinoma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPQU9oSUtWVno4SUNvNG9BbkdESFh4YWJEMFR5NWZUS3J0MW13NFZzQjk3cmd5emdmOUtUbGRTaWZTTnhVSXFhM1R4UF9xLVRXSmRsZlVLaXoycFNJWGJjRldnd2FVUjdoZlVHelF5RG5pQ212SVJvVnR4bkhoSGRKbWQ4UkRnS052MHhwUnl3bWVFZG52aDlFZFBZZ0dmaGZFQ3hmMGRGLVJsc19uYTdyNGdB?oc=5" target="_blank">Enfortumab Vedotin/Pembrolizumab Maintains OS Benefit in Urothelial Carcinoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
Urology Timesgeneral

FDA approves enfortumab vedotin plus pembrolizumab for MIBC

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPT2dHbDJGempFdjNWUDlnVlRzdDY0amdNNXlCVHU2NmhLSllzOWtwd0pCQWhJQ2thMFhqazFhalJVMEIzR2kyb2VEVTJHSE42SzZiczYzU1JtVkN2ZzBvRjNGZjJvS0NsYnBidXp4UUdCSDJ1NEtsNDVxTF9PaDFBbVFURzBjSWZzNzQtVl92UFVWSzZWOVB1Vw?oc=5" target="_blank">FDA approves enfortumab vedotin plus pembrolizumab for MIBC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Enfortumab Vedotin Plus Pembrolizumab Sustains Survival Advantage at 3.5 Years
Pharmacy Timestech

Enfortumab Vedotin Plus Pembrolizumab Sustains Survival Advantage at 3.5 Years

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPQ09XVmktYmF5WW1zUlp4dXl0eFU2Ynpxai13aHNYQjdENVhfWmNCMjNiUk11MjVvWGVPYlUwNlFKb0xLTzJGUWxXMHV6ZU15TXgtNDFubjBtVUFIRkdwSUR2THlCT3k3NHVRaEpNaE9oRllqd214RENsal9nLW1tal9ubGU5c3FlVU01MldVRzcwTkJITUVOVWFsOEJlRWQwQmstYVhxS0k0N3JELUZSNnhhTm4?oc=5" target="_blank">Enfortumab Vedotin Plus Pembrolizumab Sustains Survival Advantage at 3.5 Years</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The ASCO Postgeneral

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPT2ZDTUl2X05WNzA0WnhQUF9UX1htUEUwVmpmbWYxal9Yb2Z6eV9KcnEzaTZzdDN4aFg3VkxBcGhNMFpIYmFxZkYxUDB5RHlTQkxHbWVjNlBaZk84YkdCa1pmaGpFY3NQREl0UEh4eVB0ZW1DQ1I1UnVhTlZzVF90OFNfYTBYR0NaTVZpQVhVRC1nRjltT3lXeGJSVnh4ckFqY1RQQVVaS2NTNlpNeG1RZnFnT0MzaFpaRHJJTGRZRXp6cFdtSUV4S3Z5NTFsUDlHZmV6Y2c4Z01Pck93b0VmSGZuNnVQYi12ejNabGpEeUhPVEtSWDJUbHJidmdIQW8?oc=5" target="_blank">Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
NEJMgeneral

Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTFBoNWw5VzA0cTZwbS1Dd1N3WVpUOFNTLW0yYzIyRUNYa1g4c1RBSjF1Q0J0T3RVdHp0bWJlMUVETXhPMHZXbExuVHpUWk8waDNQTmljTzh0NXU0ZEhHMFE?oc=5" target="_blank">Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
KEYNOTE-B15: Enfortumab Vedotin Plus Pembrolizumab Improves OS, EFS, pCR Rates Over Chemotherapy in MIBC
ASCO Daily Newsgeneral

KEYNOTE-B15: Enfortumab Vedotin Plus Pembrolizumab Improves OS, EFS, pCR Rates Over Chemotherapy in MIBC

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNOEUyUXNhM3NGSUY2NmVXeDF3cngwQ3E4ZTg3dUx0V1BEcnNnNExoUnE5MmpWRE9SQ0d1dHZzRW9YM3ZwcnRNVHVQZHdKOEx6dFB1WFZBRDdGSmcxRUlGa3VwakJJM3VsZ25sYl9fOWs5b0xheGxwVTM4Zmt2VnBycXMwYTFKQ3ZOVjh3U3lWQTlNU19LMGhxTHRYTFlnajh3ZUNoaUs1MjAxal9MVHRPZDEzRHQ?oc=5" target="_blank">KEYNOTE-B15: Enfortumab Vedotin Plus Pembrolizumab Improves OS, EFS, pCR Rates Over Chemotherapy in MIBC</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study
Frontiersgeneral

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNR05wSWQ1Vk53dzBKWmp2eWNIcGNnQm5WY3Y1OTZ4bk9kNzZ2MFViSnFLMFhGT1d4R0hneERuVkVfa3NVb1gySlJ5RUxua0s1TDF2Y0djNmlxS3Y5ckl4VVZoTlFGeW5SY1JkZWNFOEUtbXV6TXJLNEo0bVdnbFdSRUpiR3RWODJrenM1Vlg2eTNhSTFlX1E?oc=5" target="_blank">First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
In MIBC, Enfortumab Vedotin Plus Pembro Cuts Risk of Recurrence or Death Nearly in Half for Chemo-Eligible Patients
AJMCgeneral

In MIBC, Enfortumab Vedotin Plus Pembro Cuts Risk of Recurrence or Death Nearly in Half for Chemo-Eligible Patients

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQN3ktUFh2a3lESzAtZlFRaFRnWjdMMEo1U1BGQ2E0VHVDcl9zekw2MGw2bnJsVUd4NTQ0V2JkbHJBSllpVXpLVHNJQzZqLW5rYkxxVEF5X2FBcEVuYmpEeEFKTS05MUF5M3lzbHQxQVU2UkZXMHNmLUl0WUtSdWc4SXlqcG5PREdPTFN4UHZYNkhoUVZwYmxORzh0bTFGYXg5RUEyODdzc1JhUUNzOW9qRjhaSTVtT3pQUHotRHlHSUVRSDlfOFBJaTZxYkpBSktZMm5iMW1qaw?oc=5" target="_blank">In MIBC, Enfortumab Vedotin Plus Pembro Cuts Risk of Recurrence or Death Nearly in Half for Chemo-Eligible Patients</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscapeworld

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMVB3bjgtTGNwcjRTXzZDYnUxRWZUQWwxNGYxVTZlMUtTLVV0MWhpb0hfemNxeURSeUJXYkhVNGxDNVVwYzRRcVhHaU5UX1dHUVFVQkZTVkZQRU9xM0t4Nkphdmo4OFZielQtUkUtd0NGNEdvOWZjaDZvY2k2c2NnR0tXa01rUURHeGU0SVNGY1RhZ3RDZHJ5ek5DRmtLcmI1TGoxS0xJOVFxdw?oc=5" target="_blank">Real-World EV Plus Pembro Success Seen in Urothelial Cancer</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab: Results from UNITE
EMJworld

Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab: Results from UNITE

<a href="https://news.google.com/rss/articles/CBMiwwJBVV95cUxQa3NlcHR6MmdwYWF1RV9jcWU1bTktTW1ONHpDOTRSbVBCNmNGYUVqMW12Y0x3YUo1dEVGaGJ0cHU5SGw2NVUxaHN1VlN4UkR6Sk1wRzlOT0l4VlBNa05adTNsd1Q5WWxURDg0YjBvVE12d05pNEo1bEVSZDNqSUowR0E2MENaM1JDTVEtei1qaWVRMFZza1pPci0wMzVNcFBCVms3QkVFNHlPLVlWelJSSnViZ1VSX2g4Z1h4TGc2anRFVnZvUEtfa3psT19taFYxZFBOVFNnTlB6QjR2Ykk1MWdBaDVmYWtXamE0UTNwZGluZlRUbHNEc0M1ZVhHelJkS21jVVhyN3V4ZFVQdmg4Zzl2NW55S0c1Q25rU2RaME9NX21IZS10eDFqWEZFQ2ZIM2hnSGctbmlVSVF1WTk2N2xWYw?oc=5" target="_blank">Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab: Results from UNITE</a>  <font color="#6f6f6f">EMJ</font>

Read Full StoryMore like this
Enfortumab Vedotin Plus Pembrolizumab Beats Chemo in Muscle Invasive Bladder Cancer
Oncology News Centralgeneral

Enfortumab Vedotin Plus Pembrolizumab Beats Chemo in Muscle Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOWDJHOFU1bEFELUxmQWVtVzhxRXpSY2NhcVlMbFFJWC0tc2N6ZXZpdGxUemo3ZWRUTW1GajQ0TXNSd3h5RjFCQl96dDZpU1E3cnJlQkg4ZmYxdTVWZWhPSHR0N3FyNGFjMDhRU181cHpZZ013TlhzVXgtamw1Wm9VZUZyVmJMQ1htVHQzQVA2TndUd1JDZXFtZldKMTd6X2JCNkpsbzNaazRHT0h6T2N6a25QV2pCOFBlWHpUd0NLVQ?oc=5" target="_blank">Enfortumab Vedotin Plus Pembrolizumab Beats Chemo in Muscle Invasive Bladder Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC
CancerNetworkgeneral

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQdHZTRzJHdHZoOV9TazA0cl8tb19JVkhwY1V0TjlwUjdoX211OV91XzdzOTdWRDhwWUxoNkRfNVFiSDhCcmxNYXNUVmJFb0VYTUVhN2wxaHI2X3dsVlNiSjJTalNOclVsUWNaWmZvYWxwUkFBRDJWXzd5MmpvaF9IZEJEUlJPSnJTUWxSRnhkSEFsMmFScURfZG5yYmpSRThUeFBjVVVHWUFPTktT?oc=5" target="_blank">EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
EV+P maintains OS benefit at 3.5 years in metastatic UC
Urology Timestech

EV+P maintains OS benefit at 3.5 years in metastatic UC

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOUkFIRFQyektBeTJnMllkMFY4UURIS3NmU2JJSzFvRE9qc2MzM2JvUzhBSFItSlRIZEc2N20zUWFhMUVkT0ExUVo1TEh6aHFwc0NrTGF2dEh6V1NDMHBMaFVaUnJncWhKOXdLUW10VDM0VDZOVzNsckNTLXZqWWxQUThoRktCdkNWa2tweEkyd1gtTTA?oc=5" target="_blank">EV+P maintains OS benefit at 3.5 years in metastatic UC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care
OncLivegeneral

FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUTloSEpUWFNqa0JZeHk5ZTg4RGY2cjEtXzVRNnREd0lPUFVPS25MNXFWTFhkdzl2a3RVTm5hb2JCZWJxek9rZWNfbXlhdzRoSXVrVmhxeHVhalFtQ19DNWZqaFBfUl95TG1iMDhkbGY1MVZIZV82cEwwS0FNcWlIZkl3eXQ1WGZ5WU5XZExyOXNTakRHWG9oTk15cFhUVjZLU2c5YjBnVVZhYW5nbVJtVjQzSDFNZ1R1N0dlREg5MmNwb0hSX19aNnhneEhtWnM3UFg4?oc=5" target="_blank">FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Grants Priority Review to Enfortumab/Pembrolizumab in Perioperative MIBC
Targeted Oncologygeneral

FDA Grants Priority Review to Enfortumab/Pembrolizumab in Perioperative MIBC

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQbFRfNFN2REgwb0dIVTNNanNqdS1PbzE3UVZSOEZmVzE0X2xSNy04cXg1eE83OE9lbll6NGI5VkdBUE5lNnBaM1ktT2pLdlMxQV9ZMnJ5TFZ6ZktsMklpbGxjdjcycnBfWE90WkJWcmxrVnp4WUdjYXoyUnRKM2FXQXlBVDhuTFpaamVwd0dQRWhrVHFrRExZRG11VVgtNjFMWU5DZ2hEWVVfZjYwT0hScnV4bU5IOGdGTXB0OS1YZkUxakhsOVJRVDZn?oc=5" target="_blank">FDA Grants Priority Review to Enfortumab/Pembrolizumab in Perioperative MIBC</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
Urology Timesworld

European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTGwxUFA5WExFcExSZUFTazZpM2JhZ3JlUEpWVkNFN0hudC1CaHBKZG54WmRpU2tQakJkT19XREpfLVdvM3BQazVvQlB0UGl3aFdNVUFqTFZIS3MxRnR2MWNOWEswN21RR0FzN1lZOUdhYlZ0SjFlYlJ1dTE4d0ZrckRMeFl3aGlFQjRjSE5fNzdRcnJkN3RVeUswQzZTRW1JZ2NxZldwazcxQUlwUFZNalpoWXZZX1N2ZlJPU0VkS1o?oc=5" target="_blank">European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
OncLivegeneral

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVWhGVnJZMzJ3NFNiakNabk94SElWZDROdjRpLVVXZ0tzeERidmgybFJDM2JqeGMtS2h1LWNRZy1HclBueG9QbmlqZGhLSXdPajlDOTVaczkwWVd5YjZ6ZlRDTzFWUGJMR3pPTEZwM29TSzVoUlVLTTBhSjZLT2JZYUVYSy1OSmZ2U3VnV3dqdGEzeWNJRFloOFdueVVpaW9zVWNZa2pXcmc5NTFadTdZUkVXZU1rUlFWd2VobG5sa2o?oc=5" target="_blank">FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
CHMP recommends approval of EV/pembrolizumab for cisplatin-ineligible MIBC
Urology Timesgeneral

CHMP recommends approval of EV/pembrolizumab for cisplatin-ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPeUw5UmRhUmpJRmxBLV9jYVNlSk9PUkN5YUg0WnU2VUN3MVpzVFJpMTk4Z096UTBPOXNkWXNPc1RfV1kwZU5Uc19INUdzUG1pb21uLU5ORENCRTlzczQzZ2VxZkY3bW41b0s5eFg5bjE4aEdkanU4TVpGSGZBVTlnd2xfTEFaWFJoU1RjaVJwREg3eEhVQVRkUExveU1QV1Rob2NnT2JaYnl0NUtx?oc=5" target="_blank">CHMP recommends approval of EV/pembrolizumab for cisplatin-ineligible MIBC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC
The American Journal of Managed Caregeneral

FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOOXV3ME1pUE1wTldBdFg3dnJReVExbjlxZDE4NC1KbjJxRFRoekJBbURzTm8ybFdaZnZoRElGeEVTVnB5VzhqbVVUdU94X0hTX0VKT0U0ZnFzUUVQeC1lVGtPeDMxcTUycl9ERS1ycDBrUVJyMGNkTy1tNksxZXRrX18wNXN2NmNtaGJ5RnRn?oc=5" target="_blank">FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
The ASCO Postworld

Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOUjI3SzdPaWgwcE13NFBsWGE5THVweUNGQXZ6ZHVxMENVN1pVRUJnRTdiV19XQ3ZVeXd1eFc3UmRiQTV1UElxdWt2OTctUEtQM0xvN0VVQURCbkt1MWFZM0NOSG15MGUzMmE5dnZtWXRfVF9wMWZQT3dpVmJwejdGUWVDZm5uOVc1WDQ2bnA3RkJrWGZneGlZWHZ1RGpuNU5CWmpaTVNUeTNzRW51N0Q2YUdXbWRHeVJFcG1uemplZjBaamtWU0VGckNPZXVYNzlDRXhjakc0NGV3bFNjUVBKVDBheEE4VFJvNkE?oc=5" target="_blank">Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Metastatic urothelial carcinoma: Enfortumab vedotin plus pembrolizumab outperforms platinum chemo in routine practice
Vera Healthgeneral

Metastatic urothelial carcinoma: Enfortumab vedotin plus pembrolizumab outperforms platinum chemo in routine practice

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQZWRZajJzQTdZRTc0b1l0TUxwU2FhUHU1RElPS1lXU3NWWjZCNmFTSlVuWmgtS3JUSWY4Um5Od2NvQW9wUVk3SUtsMkhlTnpjcWlEcTM3aVJmNmJMajhLT1phUGI2QjVmQmxRRFpTbzBncXhsVHY4VDNJRE8zNV8tRXRDelJyWlN4SWpXMHJjV1BOZGhycXZxNnhoVXB5aDJaY3VLMENtM0JydXl5UW9v?oc=5" target="_blank">Metastatic urothelial carcinoma: Enfortumab vedotin plus pembrolizumab outperforms platinum chemo in routine practice</a>  <font color="#6f6f6f">Vera Health</font>

Read Full StoryMore like this
Real-World Data Support EV-Pembrolizumab in Advanced Urothelial Cancer
Oncology News Centralworld

Real-World Data Support EV-Pembrolizumab in Advanced Urothelial Cancer

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQT2h1blB0R2wzbl9QLV9IQ2o3VG1TUWFzMklkVFp5YWpSRFI4TTdrM3JYVXc0OFMyRmNoU1Njc05Od1RKXzZwRVlYSGlDOS1lYURYdG1WX1Nzc3c5RmdWSGg1LTk0NlNrWHdjbF9sa0JtLVhUa0ZraUJOa2hob2dnMUVBc1pCV1FUR092SWdNN3ZDWlRzTzZEUzRwX2Vtd1pZRTAwbDktNWZWV0NJbURfSXR5SHBiYlNlVE5DQWZR?oc=5" target="_blank">Real-World Data Support EV-Pembrolizumab in Advanced Urothelial Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC
OncLivegeneral

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQa0ZaNlFySklaR2dhUlBLT3ZFMnM2LXk2Z1kzVWdvRDhwSlBaOTNMNExxckJ5SkdjLWRod3NJbVVjZnhuMGlKZ05WeGJSYzhhUjJ6NzBjMVdfMXM0THdOUE9PcWZCX0xuVDVEX3o3SVQ2MkNtb19qQjJHSmZXYTNhbjQyX2xnTnZ1VmVuLTlfdjBRM3Ywd011aFVXdEZ4LVI4MEpqZ25sLU14RXBtbVYxUnFvOEFDVl8tQ3NFUjAxYmxTM25GTFFQLXB2VQ?oc=5" target="_blank">Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC
OncLivegeneral

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOMHNUUm1kaGhrRVRySWdzTE5GWEg2NmxuV2lyN0trV2dJSDJzYzdHV3BiOHRFYWxDOW5tSFpHZ0tWX0F3YmkycGV2SVZZZXZJYXJQcUhKNnZKQ29haF9oQzQwUU9aTGhYY1J0aXhGNGxKSzBvOHpWTVdUdno1RjQ4LTZLSnE5UTkzdUFIZUQ4NWJGQ0xmMU9KTHRZTnZORjByTXFRbkhweVZxRjJyamVIX25Vd05MR2ZZNHJ1SGhmeS1oV25iMDlvdzVIUWxmQ3htT21nbTNR?oc=5" target="_blank">FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
The American Journal of Managed Caregeneral

Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxQcDhFLXhyWU1hR1NickFXNkdQTGxVOGx5OHFYcVl3OHE3Ukd2VzNBbnVpMzN4ckFFM3BEd2Fab0xteklfY1NCcTkyc1VvZURGMm5PYlZGLXRhWXNEQjNKSi10aGl4dVRteHVFem5Fd2JfSTl4cjdhTW9oNmtlQ0x3WkVJeldhNFdCZmNibDljb0NZS1dWUjluVUpreUd5QU9udklXSC1nNWU5cElsUl9scERwY25iY0E1T3I3R3ZtMkxWdTliSEROYUYyVHBaNVphYXF6U2RNNHVYaDZFR0Jub2I5R1lJaEs2VGxLWFYxbkZFWEdVaHc?oc=5" target="_blank">Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
KEYNOTE-905 Trial Data Met With Cheers at ESMO 2025, Marking “New Era” for Bladder Cancer Care
Oncology News Centralgeneral

KEYNOTE-905 Trial Data Met With Cheers at ESMO 2025, Marking “New Era” for Bladder Cancer Care

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWEFoc1ZvaVZ3QWhnZ0diMG11TVVDaGM3RUVXNWRPelZYR0FaNzBpMFRUNzRkNU40YlZLZ0IzYmkzNVVBN3ppQWNaa0x4VFRQU1Z0bl9UdlhTM2pDTEVvWUNfY05iYUM3aFFIaE84MUFpV3hnYk9oT0R3dE9Vb3FPRWRlNWw0UThYZTQxZFZDUlRXZmVyLUZNUkZ1bm9XNUVrcVYtQmVOX1JoRWhCLWVkSXJ1OEFNZmRTUV9haklZcjFwZTlKaXpBNTJlRmdiRVpNa3RhQ2M5cw?oc=5" target="_blank">KEYNOTE-905 Trial Data Met With Cheers at ESMO 2025, Marking “New Era” for Bladder Cancer Care</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC
CancerNetworkgeneral

EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNV01ZZWpjSm1lLXRrcG5qU0tVQ3k5SlFjX2NCMWJpX09IRWVvdG9ncFphN2F2TU4yZkNGXy1wSlhIQnRwRFVQSWN3S010N21WT1JCS3V0YmUzaFJDajJXWUFURndxeEVNQ0xxMF9SSFBHWTg4VUdjTEZON09UQmFkM2xMWTh0Sjl2TDdjMTVWZldGcXhjTC1aZF9RRjFzR0xsTjBoUzMtWGRpQjRWVVpz?oc=5" target="_blank">EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"Enfortumab Vedotin Plus P" — Live Google News Trends & Headlines